The GLP-1 medication category — the most consequential development in obesity medicine in a generation — has become, in 2026, the dominant pharmacological intervention for clinically significant weight loss. This article is a reported look at what these medications can actually do, what they cannot, and what a patient on a GLP-1 needs to understand about the difference between “losing weight” and “losing weight well.”
What the GLP-1s are and what they do
Glucagon-like peptide-1 (GLP-1) receptor agonists were originally developed as type-2 diabetes drugs in the early 2000s, and the weight-loss effect was first noted as a side effect in those diabetes trials. The mechanism is several mechanisms operating together: the medications slow gastric emptying (food stays in the stomach longer, the sensation of fullness lasts longer), they act on the appetite-regulating circuitry in the hypothalamus (the drive to eat is meaningfully reduced), and they influence reward-related food behavior in ways researchers are still mapping out (the “food noise” reduction that patients consistently describe).
The headline weight-loss outcomes from the major trials are, by historical standards, extraordinary. Semaglutide 2.4 mg weekly produced an average 14.9% loss of starting body weight at 68 weeks in the STEP-1 trial. Tirzepatide 15 mg weekly produced an average 20.9% loss at 72 weeks in the SURMOUNT-1 trial. The next-generation triple-agonist agents in late-stage trials are reporting average losses in the 22% to 24% range. For comparison, the typical lifestyle-only weight-loss program — diet plus exercise — produces an average loss in the 5% to 8% range over a similar time window.
These are not marginal improvements. They are categorical improvements. A patient with severe obesity who would, on a lifestyle-only protocol, plateau at 7% loss, can on a GLP-1 reach 18% loss and stay there. That difference moves people across clinical thresholds for diabetes remission, sleep-apnea resolution, and cardiovascular-risk reduction.
What the GLP-1s cannot do
The medications do not preserve lean mass on their own. This is the single most consequential clinical issue with GLP-1 weight loss and the issue that the patient education literature is, as of 2026, still catching up to.
When body weight comes off rapidly under GLP-1-induced appetite suppression — and 15% to 20% of body weight over a year is rapid by historical standards — the composition of what comes off includes a meaningful lean-mass component. Across the published trials, roughly 25% to 40% of the total weight loss is lean tissue rather than fat, depending on baseline status, dietary protein intake, and resistance-training participation. A patient who loses 50 pounds on tirzepatide and does nothing to defend their lean mass can give up 12 to 15 pounds of that loss as muscle.
The downstream consequences of that lean-mass loss include a lower resting metabolic rate (which scales with lean mass), reduced functional strength (especially in older patients), and an increased risk of sarcopenic obesity if the patient regains weight after discontinuing the medication.
The GLP-1s are an extraordinary appetite-suppression intervention. They are not an extraordinary body-composition intervention. The body-composition outcome depends on what the patient does with the lower calorie intake, not on the medication.
What the patient needs to do
The clinical countermeasures to GLP-1-induced lean-mass loss are not novel and are not difficult. They are, however, harder to implement than people expect, because the appetite-suppression effect of the medication makes hitting an adequate protein target genuinely difficult.
Protein target. The standard recommendation for a patient on a GLP-1 is roughly 1.0 to 1.2 grams of protein per kilogram of target body weight per day (not current body weight). For a patient targeting 165 pounds (75 kg), that is 75 to 90 grams of protein per day. Reaching that target on the reduced food intake the medication produces is the single hardest practical problem of GLP-1-assisted weight loss. Protein-dense breakfasts (Greek yogurt, cottage cheese, eggs), a protein supplement, and front-loading protein in the day are the standard strategies.
Resistance training. Two to three resistance-training sessions per week, with progressive load on the major compound movements, is the most robust intervention we have for defending lean mass during a calorie deficit of any kind. The deficit produced by a GLP-1 is no exception. The training does not need to be elaborate. The training does need to be consistent.
Tracking. Patients on a GLP-1 should be tracking their daily calorie intake and — more importantly — their daily protein intake. The appetite suppression makes it surprisingly easy to undershoot the protein target without realizing it; what feels like “I ate plenty today” can register as 45 grams of protein when the actual target was 85. A 2026 calorie-and-protein tracker that handles photo-based logging removes most of the friction of this tracking burden — patients on GLP-1s frequently report that the cognitive load of food tracking is, on its own, a barrier to adherence. We are not going to recommend a specific app inside this article; we are going to note that the tracking-tool question matters more on a GLP-1 than off one.
Periodic body composition. A DEXA scan or a calibrated bioelectrical impedance measurement at baseline, at six months, and at twelve months provides the body-composition data that the scale alone cannot. The scale will tell you that you have lost weight. The DEXA will tell you whether you have lost the right weight.
Discontinuation and maintenance
The hardest question in 2026 GLP-1 medicine is what happens after the medication is discontinued. The available data — including the STEP-1 extension data and the SURMOUNT-4 maintenance data — suggests that a substantial portion of weight loss is regained over the year following discontinuation in the absence of continued behavioral intervention. The pharmacological intervention is, mechanistically, a continuous appetite-suppression intervention; when it stops, the appetite-suppression stops.
The conservative interpretation of the data is that, for patients with severe obesity, GLP-1 therapy may be a long-term or indefinite treatment, in the same way that antihypertensive medication is. The optimistic interpretation is that an aggressive behavioral-and-resistance-training program established during the medication window can carry maintenance after discontinuation. Both interpretations have evidence behind them, and the field has not yet converged.
What is clear: discontinuing a GLP-1 without an established behavioral protocol — a calorie protocol the patient understands, a protein target the patient can hit, and a resistance-training habit the patient is committed to — is the move that produces the worst maintenance outcomes.
What we would tell a friend
A friend considering a GLP-1 in 2026 should have the following conversation with their prescribing physician before starting therapy. What is my realistic 12-month weight-loss target on this specific medication? What is my protein target during therapy? What resistance-training protocol do you recommend, and how often should I be doing it? What body-composition measurement schedule will we use? What is the discontinuation plan, and what does maintenance look like?
If the answer to any of those questions is “we’ll figure that out later,” our recommendation is to keep looking for a clinician who can answer them now. The medications are powerful enough that the protocol around them deserves the same seriousness.